Cunha, RenatoZago, Marco AQuerol, SergioVolt, FernandaRuggeri, AnnalisaSanz, GuillermoPouthier, FabienneKogler, GesineVicario, José LBergamaschi, PaolaSaccardi, RiccardoLamas, Carmen HDíaz-de-Heredia, CristinaMichel, GerardBittencourt, HenriqueTavella, MarliPanepucci, Rodrigo AFernandes, FranciscoPavan, JuliaGluckman, ElianeRocha, VandersonEurocord, Cord Blood Committee Cellular Therapy–Immunobiology Working Party of the European Society for Blood and Marrow Transplantation, Netcord and Faculdade de Medicina de Ribeirão Preto–Faculdade de Medicina de São Paulo, Universidade de São Paulo2023-01-252023-01-252016-11-03http://hdl.handle.net/10668/10578We evaluated the impact of recipient and cord blood unit (CBU) genetic polymorphisms related to immune response on outcomes after unrelated cord blood transplantations (CBTs). Pretransplant DNA samples from 696 CBUs with malignant diseases were genotyped for NLRP1, NLRP2, NLRP3, TIRAP/Mal, IL10, REL, TNFRSF1B, and CTLA4. HLA compatibility was 6 of 6 in 10%, 5 of 6 in 39%, and ≥4 of 6 in 51% of transplants. Myeloablative conditioning was used in 80%, and in vivo T-cell depletion in 81%, of cases. The median number of total nucleated cells infused was 3.4 × 107/kg. In multivariable analysis, patients receiving CBUs with GG-CTLA4 genotype had poorer neutrophil recovery (hazard ratio [HR], 1.33; P = .02), increased nonrelapse mortality (NRM) (HR, 1.50; PenAdaptor Proteins, Signal TransducingAdolescentAdultAllelesApoptosis Regulatory ProteinsCTLA-4 AntigenChildChild, PreschoolCord Blood Stem Cell TransplantationDisease-Free SurvivalFemaleFetal BloodGene ExpressionGenotypeHLA AntigensHematologic NeoplasmsHistocompatibility TestingHumansInfantMaleMiddle AgedMyeloablative AgonistsNLR ProteinsPolymorphism, GeneticProportional Hazards ModelsProtein IsoformsRetrospective StudiesTransplantation ConditioningUnrelated Donorsresearch article27811020open access10.1182/blood-2016-06-7222491528-0020https://ashpublications.org/blood/article-pdf/129/4/525/1402196/blood722249.pdf